View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 7, 2021updated 12 Jul 2022 11:13am

Sanofi partners with academic groups for Phase III breast cancer trial

Sanofi will provide funding and the investigational drug for the Phase III trial.

Sanofi has partnered with academic cooperative groups for a Phase III clinical trial of amcenestrant as an adjuvant to treat patients with estrogen receptor-positive (ER+) breast cancer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The company will initiate the global Phase III AMEERA-6 trial with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and the Alliance Foundation Trials (AFT).

Amcenestrant is an oral selective oestrogen receptor degrader (SERD). It antagonizes and degrades the estrogen receptor (ER), in turn blocking the ER signalling pathway.

The Phase III trial will compare the safety and efficacy of amcenestrant to tamoxifen in women with ER+ breast cancer who have prematurely ended their adjuvant aromatase inhibitor (AI) therapy.

BIG Executive Board chairman David Cameron said: “Adjuvant therapy helps prevent and delay the progression of disease into the later setting. However, current adjuvant therapies, like AIs, can have side effects for some women, which may cause them to discontinue the medication prematurely.

“Amcenestrant may be a potential option for women in this setting and we look forward to working with Sanofi, EORTC and AFT to investigate this further.”

Sanofi stated that many patients have disease recurrence due to the resistance to therapy, non-adherence or early discontinuation of their adjuvant therapy, such as tamoxifen and AIs.

This indicates the need for more adjuvant options to treat early breast cancer and prevent progression to advanced, incurable disease.

Under the terms of a pre-study agreement, Sanofi will provide funding, as well as the investigational drug for the AMEERA-6 trial, while BIG will perform the study within its network.

EORTC, an academic clinical research organisation, will be responsible for managing the study, data analysis, and medical management. AFT will handle the US portion of the study.

Sanofi will carry out the trial in some countries outside the academic networks’ geographical scope.

Last week, Sanofi stopped the clinical programme of venglustat in autosomal dominant polycystic kidney disease (ADPKD) after the Phase II/III STAGED-PKD trial failed to meet the futility criteria.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena